Literature DB >> 34918298

The Role of the Tumor Microenvironment in CSC Enrichment and Chemoresistance: 3D Co-culture Methods.

Michael Bregenzer1, Eric Horst1, Pooja Mehta2, Catherine Snyder2, Taylor Repetto2, Geeta Mehta3.   

Abstract

Cancer stem-like cells (CSC) are responsible for tumor progression, chemoresistance, recurrence, and poor outcomes in many cancers, making them critical research and therapeutic targets. One of the critical components potentiating CSC chemoresistance is the interactions between CSC and the surrounding cells in the tumor microenvironment. Our lab has developed several 3D co-culture models to study ovarian CSC interactions with stromal or immune cells found in ovarian tumor microenvironments. In this chapter, we use ovarian cancer as a model to describe the methodologies developed in our lab; however, these techniques are applicable to a wide range of cancers. First, we discuss our method for isolating CSC from heterogeneous tumors and for creating 3D self-assembled tumoroids in hanging drop plates, in either monoculture or co-culture with mesenchymal stem cells or monocytes/macrophages. We then discuss methods for analyzing these models with a focus on isolating cell-type-specific changes and mechanism investigation. Specifically, we describe lentiviral transduction and flow cytometry as established and robust methods to identify and separate each cell type for downstream analysis. We then describe methods to examine CSC functionality with transwell migration assays and colorimetric MTS-based proliferation assays. Finally, we demonstrate enzyme-linked immunosorbent assays (ELISA ) and quantitative polymerase chain reaction (qPCR) methods as mechanistic investigation tools to decouple paracrine and juxtacrine interactions. These methods have wide-reaching applications in cancer research from basic biological investigations, to drug discovery, and personalized drug screening for precision medicine.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cancer stem-like cells; Chemoresistance; Co-cultures; Juxtacrine; Ovarian cancers; Paracrine; Three-dimensional; Tumor microenvironment

Mesh:

Year:  2022        PMID: 34918298     DOI: 10.1007/978-1-0716-1956-8_15

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  17 in total

1.  Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes.

Authors:  Stefan Kommoss; Boris Winterhoff; Ann L Oberg; Gottfried E Konecny; Chen Wang; Shaun M Riska; Jian-Bing Fan; Matthew J Maurer; Craig April; Viji Shridhar; Friedrich Kommoss; Andreas du Bois; Felix Hilpert; Sven Mahner; Klaus Baumann; Willibald Schroeder; Alexander Burges; Ulrich Canzler; Jeremy Chien; Andrew C Embleton; Mahesh Parmar; Richard Kaplan; Timothy Perren; Lynn C Hartmann; Ellen L Goode; Sean C Dowdy; Jacobus Pfisterer
Journal:  Clin Cancer Res       Date:  2017-02-03       Impact factor: 12.531

Review 2.  Lost in translation: animal models and clinical trials in cancer treatment.

Authors:  Isabella Wy Mak; Nathan Evaniew; Michelle Ghert
Journal:  Am J Transl Res       Date:  2014-01-15       Impact factor: 4.060

Review 3.  Cancer stem cells: A review from origin to therapeutic implications.

Authors:  Mohammad Reza Atashzar; Rasoul Baharlou; Jafar Karami; Hamid Abdollahi; Ramazan Rezaei; Fatemeh Pourramezan; Seyed Hamid Zoljalali Moghaddam
Journal:  J Cell Physiol       Date:  2019-07-08       Impact factor: 6.384

4.  A single-cell landscape of high-grade serous ovarian cancer.

Authors:  Benjamin Izar; Itay Tirosh; Elizabeth H Stover; Isaac Wakiro; Michael S Cuoco; Idan Alter; Christopher Rodman; Rachel Leeson; Mei-Ju Su; Parin Shah; Marcin Iwanicki; Sarah R Walker; Abhay Kanodia; Johannes C Melms; Shaolin Mei; Jia-Ren Lin; Caroline B M Porter; Michal Slyper; Julia Waldman; Livnat Jerby-Arnon; Orr Ashenberg; Titus J Brinker; Caitlin Mills; Meri Rogava; Sébastien Vigneau; Peter K Sorger; Levi A Garraway; Panagiotis A Konstantinopoulos; Joyce F Liu; Ursula Matulonis; Bruce E Johnson; Orit Rozenblatt-Rosen; Asaf Rotem; Aviv Regev
Journal:  Nat Med       Date:  2020-06-22       Impact factor: 53.440

5.  An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity.

Authors:  Oded Kopper; Chris J de Witte; Kadi Lõhmussaar; Jose Espejo Valle-Inclan; Nizar Hami; Lennart Kester; Anjali Vanita Balgobind; Jeroen Korving; Natalie Proost; Harry Begthel; Lise M van Wijk; Sonia Aristín Revilla; Rebecca Theeuwsen; Marieke van de Ven; Markus J van Roosmalen; Bas Ponsioen; Victor W H Ho; Benjamin G Neel; Tjalling Bosse; Katja N Gaarenstroom; Harry Vrieling; Maaike P G Vreeswijk; Paul J van Diest; Petronella O Witteveen; Trudy Jonges; Johannes L Bos; Alexander van Oudenaarden; Ronald P Zweemer; Hugo J G Snippert; Wigard P Kloosterman; Hans Clevers
Journal:  Nat Med       Date:  2019-04-22       Impact factor: 53.440

6.  Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer.

Authors:  Shili Xu; Fedora Grande; Antonio Garofalo; Nouri Neamati
Journal:  Mol Cancer Ther       Date:  2013-03-27       Impact factor: 6.261

7.  Tanshinone IIA inhibits breast cancer stem cells growth in vitro and in vivo through attenuation of IL-6/STAT3/NF-kB signaling pathways.

Authors:  Caiyu Lin; Li Wang; Hong Wang; Liuqi Yang; Huijie Guo; Xiujie Wang
Journal:  J Cell Biochem       Date:  2013-09       Impact factor: 4.429

Review 8.  Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update.

Authors:  Joseph A Clara; Cecilia Monge; Yingzi Yang; Naoko Takebe
Journal:  Nat Rev Clin Oncol       Date:  2019-12-02       Impact factor: 66.675

9.  Ovarian cancer stem cells and macrophages reciprocally interact through the WNT pathway to promote pro-tumoral and malignant phenotypes in 3D engineered microenvironments.

Authors:  Shreya Raghavan; Pooja Mehta; Yuying Xie; Yu L Lei; Geeta Mehta
Journal:  J Immunother Cancer       Date:  2019-07-19       Impact factor: 13.751

Review 10.  Ovarian cancer stem cells and targeted therapy.

Authors:  Vahideh Keyvani; Moein Farshchian; Seyed-Alireza Esmaeili; Hadi Yari; Meysam Moghbeli; Seyed-Reza Kazemi Nezhad; Mohammad Reza Abbaszadegan
Journal:  J Ovarian Res       Date:  2019-12-06       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.